Viking Therapeutics, Inc. (VKTX)

Name: Viking Therapeutics, Inc. (VKTX) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001607678 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Viking Therapeutics, Inc. reported revenue of $0. Over the twelve months to 2026-06-30, revenue was $0.

Key ratios (year ended 2025-12-31)

-56.3%

Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-09-28

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
R&D Expense	$509.32M	$344.95M	$101.64M	$63.81M	$54.23M	$44.98M	$31.93M	$23.56M	$19.04M	$13.74M	$9.00M
Operating Income	-$560.02M	-$393.34M	-$150.92M	-$100.83M	-$70.36M	-$55.68M	-$42.66M	-$32.69M	-$26.16M	-$19.07M	-$13.85M
Net Income	-$534.80M	-$359.64M	-$109.96M	-$85.89M	-$68.87M	-$54.99M	-$39.49M	-$25.78M	-$22.06M	-$20.58M	-$14.73M
EPS (Diluted)	n/a	-$3.19	-$1.01	-$0.91	-$0.90	-$0.71	n/a	n/a	n/a	n/a	n/a
Total Assets	$521.90M	$715.73M	$908.32M	$368.49M	$168.53M	$210.66M	$256.50M	$284.26M	$302.31M	$22.12M	$14.54M
Total Liabilities	$113.58M	$76.67M	$28.04M	$20.07M	$23.21M	$8.78M	$12.16M	$7.14M	$4.56M	$8.66M	$6.49M
Shareholders' Equity	$408.32M	$639.06M	$880.28M	$348.42M	$145.32M	$201.88M	$244.34M	$277.12M	$297.75M	$13.46M	$8.04M
Cash & Equivalents	$125.75M	$165.81M	$26.68M	$55.52M	$36.63M	$26.37M	$29.12M	$8.38M	$24.78M	$8.99M	$3.08M
Operating Cash Flow	-$418.44M	-$278.69M	-$87.79M	-$73.38M	-$48.40M	-$47.59M	-$21.78M	-$24.75M	-$18.75M	-$14.76M	n/a
Share Repurchases	n/a	n/a	n/a	n/a	$6.79M	n/a	n/a	n/a	n/a	n/a	$229
Shares Outstanding	116.65M	114.79M	111.57M	100.11M	78.26M	78.25M	73.22M	72.41M	71.74M	35.82M	20.82M
Weighted Average Diluted Shares	n/a	112.67M	109.04M	94.35M	76.83M	77.20M	n/a	n/a	n/a	n/a	n/a
EPS (Basic)	n/a	-$3.19	-$1.01	-$0.91	-$0.90	-$0.71	n/a	n/a	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView